Trials / Completed
CompletedNCT02120456
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 43204 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-04-22
- Last updated
- 2025-03-06
- Results posted
- 2019-01-04
Locations
21 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02120456. Inclusion in this directory is not an endorsement.